Compare Nomura Holdings Inc (NMR) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nomura Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nomura Holdings Inc trades at $9.4 (market cap $27.46B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 4.4× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays a 3.45% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NMR | VRTX | |
|---|---|---|
Market Cap | $27.46B | $121.95B |
Sector | Financials | Health |
52-Week High | $10.04 | $529.59 |
52-Week Low | $6.39 | $366.54 |
Dividend Yield | 3.45% | — |
Enterprise Value | — | $116.69B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
